Page last updated: 2024-10-23

benserazide and Dysphagia

benserazide has been researched along with Dysphagia in 3 studies

Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.

Research Excerpts

ExcerptRelevanceReference
"The bioavailability of levodopa-benserazide in a standard capsule and a new dispersible tablet was compared in Parkinsonian patients, with (n = 8) and without (n = 8) swallowing difficulties."6.66Bioavailability and acceptability of a dispersible formulation of levodopa-benserazide in parkinsonian patients with and without dysphagia. ( Bayer, AJ; Day, JJ; Finucane, P; Pathy, MS, 1988)
"The bioavailability of levodopa-benserazide in a standard capsule and a new dispersible tablet was compared in Parkinsonian patients, with (n = 8) and without (n = 8) swallowing difficulties."2.66Bioavailability and acceptability of a dispersible formulation of levodopa-benserazide in parkinsonian patients with and without dysphagia. ( Bayer, AJ; Day, JJ; Finucane, P; Pathy, MS, 1988)
"Dysphagia is a frequent and potentially serious complication of Parkinson's disease (PD)."1.30Swallowing difficulty in Parkinson's disease. ( Chiang, JH; Fuh, JL; Lee, RC; Lin, CH; Liu, HC; Wang, PN; Wang, SJ, 1997)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19901 (33.33)18.7374
1990's2 (66.67)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fonda, D1
Schwarz, J1
Clinnick, S1
Fuh, JL1
Lee, RC1
Wang, SJ1
Lin, CH1
Wang, PN1
Chiang, JH1
Liu, HC1
Bayer, AJ1
Day, JJ1
Finucane, P1
Pathy, MS1

Trials

1 trial available for benserazide and Dysphagia

ArticleYear
Bioavailability and acceptability of a dispersible formulation of levodopa-benserazide in parkinsonian patients with and without dysphagia.
    Journal of clinical pharmacy and therapeutics, 1988, Volume: 13, Issue:3

    Topics: Aged; Aged, 80 and over; Benserazide; Biological Availability; Capsules; Consumer Behavior; Deglutit

1988

Other Studies

2 other studies available for benserazide and Dysphagia

ArticleYear
Parkinsonian medication one hour before meals improves symptomatic swallowing: a case study.
    Dysphagia, 1995,Summer, Volume: 10, Issue:3

    Topics: Administration, Oral; Aged; Benserazide; Bromocriptine; Deglutition; Deglutition Disorders; Drug Adm

1995
Swallowing difficulty in Parkinson's disease.
    Clinical neurology and neurosurgery, 1997, Volume: 99, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Barium Sulfate; Benserazide; Contrast Media; D

1997